Kymera Therapeutics (KYMR) Interest Coverage Ratio (2019 - 2026)
Kymera Therapeutics (KYMR) posted quarterly Interest Coverage Ratio of 0.2 for Q1 2026, up 66.41% year-over-year from 0.12 in Q1 2025, and up 44.61% quarter-over-quarter from 0.37 in Q3 2025.
Powered by 
Analysis
Kymera Therapeutics (KYMR) Interest Coverage Ratio (2019 - 2026) Analysis & Trends
Kymera Therapeutics (KYMR) has reported Interest Coverage Ratio for 8 consecutive years, with 0.2 the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest Coverage Ratio rose 66.41% year-over-year to 0.2; the TTM figure through Mar 2026 stood at 0.87 (up 61.65% YoY), while the FY2025 annual figure was 0.87, up 21.24% from the prior year.
- Interest Coverage Ratio improved to 0.2 in Q1 2026 per KYMR's latest filing, from 0.37 in the prior quarter.
- Across five years, Interest Coverage Ratio topped out at 0.2 in Q1 2026 and bottomed at 5047.19 in Q4 2024.
- Historically, Interest Coverage Ratio has averaged 354.87 across 5 years, with a median of 0.55 in 2025.
- Annual changes were most pronounced in 2023 — Interest Coverage Ratio jumped 99.94% — and 2024, when it plunged 1296770.02%.
- Kymera Therapeutics' Interest Coverage Ratio stood at 623.06 in 2022, then surged by 99.94% to 0.39 in 2023, then slumped by 1296770.02% to 5047.19 in 2024, then surged by 99.99% to 0.37 in 2025, then surged by 44.61% to 0.2 in 2026.
- Business Quant data shows KYMR's Interest Coverage Ratio at 0.2 in Q1 2026, 0.37 in Q3 2025, and 0.63 in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -493.00 |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -21.24 |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 8.18 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 2.82 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 1.42 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.08 |
| 10 | Kymera Therapeutics | 11.52 Bn | 10.83 Bn | - | -933.42 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -933.42 |
| Mar 31, 2026 | -1,379.57 |
| Dec 31, 2025 | -1,087.73 |
| Sep 30, 2025 | -944.09 |
| Jun 30, 2025 | -782.94 |
| Mar 31, 2025 | -1,033.69 |
| Dec 31, 2024 | -1,368.73 |
| Sep 30, 2024 | -1,202.07 |
| Jun 30, 2024 | -834.84 |
| Mar 31, 2024 | -838.13 |
| Dec 31, 2023 | -371.38 |
| Sep 30, 2023 | -1,402.66 |
| Jun 30, 2023 | -903.81 |
| Mar 31, 2023 | -824.11 |
| Dec 31, 2022 | -654.75 |
| Sep 30, 2022 | -1,246.72 |
| Jun 30, 2022 | -995.37 |
| Mar 31, 2022 | -900.80 |
| Dec 31, 2021 | -666.55 |
| Sep 30, 2021 | -409.10 |